

## THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- An analysis of real-world outcomes for elderly patients with AML in the United States demonstrated that it is common for these patients not to receive any specific anticancer treatment.
  - True
  - False
- A single-arm Phase I study evaluating venetoclax in combination with an HMA for elderly patients with previously untreated AML demonstrated \_\_\_\_\_.
  - Response rates of 70% to 80%
  - Durable responses
  - Substantial toxicity
  - All of the above
  - Both a and b
  - Both a and c
- Which of the following strategies is typically employed to help mitigate venetoclax-associated TLS?
  - Dose escalation during the initial days of venetoclax treatment
  - Frequent monitoring and hydration
  - Administration of prophylactic allopurinol
  - All of the above
  - Both a and b
  - Both b and c
- Blinatumomab is currently FDA approved for adults and children in which of the following subpopulations of patients with ALL?
  - Minimal residual disease-positive
  - Relapsed/refractory B-cell precursor
  - Treatment-naïve B-cell precursor
  - All of the above
  - Both a and b
- \_\_\_\_\_ is an investigational tyrosine kinase inhibitor that targets both FLT3-ITD mutations and the DA35 point mutation.
  - Gilteritinib
  - Quizartinib
  - Both a and b
- Which of the following statements is true regarding IDH mutations in AML?
  - The incidence of IDH1 mutations is much higher than the incidence of IDH2 mutations
  - The overall response rate with IDH inhibitors is about 40% for patients with IDH mutations
  - Both enasidenib and ivosidenib are active in patients with IDH1 mutations and in those with IDH2 mutations
- Which of the following categories reflects the mechanism of action of blinatumomab?
  - Anti-PD-1/PD-L1 antibody
  - Bispecific T-cell engager
  - CAR T-cell therapy
  - IDH1/2 antibody
- Results of a Phase III study evaluating a liposomal encapsulation of cytarabine and daunorubicin (CPX-351) versus the conventional cytarabine/daunorubicin chemotherapy (7 + 3 regimen) demonstrated a statistically significant improvement in overall survival with CPX-351 for older patients with \_\_\_\_\_.
  - Primary AML
  - Secondary AML
  - AML with an NPM1 mutation
  - Both a and b
  - All of the above
- The mechanism of action of inotuzumab ozogamicin involves \_\_\_\_\_.
  - Binding to FLT3
  - Binding to CD22
  - Inhibiting IDH2
- The cytokine release syndrome and neurotoxicity associated with blinatumomab and CAR T-cell therapy in patients with ALL can typically be managed with corticosteroids.
  - True
  - False